Search / Trial NCT06612411

B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis

Launched by JINLING HOSPITAL, CHINA · Sep 24, 2024

Trial Information

Current as of December 22, 2024

Recruiting

Keywords

ClinConnect Summary

This clinical trial is investigating whether a probiotic called B. subtilis can help reduce symptoms in people suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-D). The study will involve patients who are diagnosed with IBS based on specific guidelines. Eligible participants are adults aged 16 to 80 who do not have other serious gut conditions, such as inflammatory bowel disease or infections, and who have not been taking certain medications like antibiotics or probiotics for at least a month before joining the trial.

If you or a family member decides to participate, you will be randomly assigned to receive either B. subtilis or a placebo (a treatment with no active ingredients) for four weeks. During this time, the research team will collect information on your symptoms and analyze stool samples to see if the probiotic improves your condition. This study is currently recruiting participants, and it aims to find out more about how this probiotic works in helping manage IBS-D symptoms.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients are diagnosed with IBS. IBS was diagnosed based on the Rome IV criteria. Subjects aged from 16-80 years old without any gut medical conditions like inflammatory bowel diseases, infectious diarrhea, colon tumors were included.
  • Exclusion Criteria:
  • Subjects who are taking any probiotics, PPIs, antibiotics or any drugs affecting uric acid levels for at least one month before the study.
  • Subjects who decline to participate into the study.

About Jinling Hospital, China

Jinling Hospital, located in Nanjing, China, is a prominent healthcare institution renowned for its commitment to advanced medical research and comprehensive patient care. As a key clinical trial sponsor, Jinling Hospital leverages its robust clinical expertise and state-of-the-art facilities to facilitate innovative research initiatives that aim to improve therapeutic outcomes across various medical fields. With a dedicated team of experienced researchers and healthcare professionals, the hospital fosters collaboration and adheres to rigorous ethical standards, ensuring the integrity and quality of its clinical trials while contributing to the global advancement of medical science.

Locations

Nanjing, , China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0